Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Sells 30 More Genome Analyzers to Broad Institute

NEW YORK (GenomeWeb News) – Illumina said today that the Broad Institute of MIT and Harvard has purchased 30 of the company's Genome Analyzers, increasing the institute's total installed base of Illumina systems to 89.

Robert Nicol, director of sequencing operations at Broad, said in a statement that the institute purchased the additional instruments to ramp up its sequencing capabilities in whole genome, whole exome, and whole transcriptome analysis.

"We are happy with the technology’s accuracy, ease of use, and scalability, as well as continued system improvements that have recently enabled us to generate multiple runs with more than 50 gigabases of high-quality sequence data," Nicol said.

Financial terms of the deal were not disclosed.

In addition, Illumina today reaffirmed its revenue guidance of a minimum of $165 million for the fourth quarter of 2009.

Last week, Illumina reported that its third-quarter revenues rose 5 percent. However, the company's Q3 revenues were about $4 million below the low end of its guidance and missed analysts' consensus estimate for the quarter, which the company blamed on a sequencing reagent quality issue.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.